Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Miranda Díaz, Alejandra Guillermina ^a   Pazarín Villaseñor, Leonardo ^b   Yanowsky Escatell, Francisco Gerardo ^b   Andrade Sierra, Jorge ^b  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b Dr Juan I Menchaca Civil Hospital of Guadalajara   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; CATALASE; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; SUPEROXIDE DISMUTASE;

ALBUMINURIA; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MICROALBUMINURIA; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ULTRAFILTRATION; URINARY EXCRETION; CHRONIC KIDNEY FAILURE; EARLY DIAGNOSIS; METABOLISM;

ALBUMINURIA; CATALASE; DIABETIC NEPHROPATHIES; EARLY DIAGNOSIS; GLUTATHIONE PEROXIDASE; GLYCATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84982792098     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/7047238     Document Type: Review

References (64)

1. J. E. Shaw, R. A. Sicree, andP. Z. Zimmet, "Global estimates of theprevalenceofdiabetesfor 2010 and2030," Diabetes Research and Clinical Practice,vol. 87, no. 1, pp. 4-14, 2010.
2. V. Vallon and S. C. Thomson, "Renal function in diabetic disease models: the tubular system in the pathophysiology of thediabetickidney," Annual Review of Physiology,vol. 74, pp. 351-375, 2012.
3. F. N. Ziyadeh,B. B. Hoffman, D. C. Hanetal. ,"Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-jS antibody in db/db diabetic mice," Proceedings of the National Academy of Sciences of the United States of America,vol. 97, no. 14, pp. 80158020, 2000.
4. F. M.-M. Lai, C.-C. Szeto, P. C. L. Choi et al. , "Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes?" Modern Pathology,vol. 17, no. 12, pp. 1506-1512, 2004.
5. Y. Almualm and H. Zaman Huri, "Chronic kidney disease screening methods and its implication for Malaysia: an in depth review," GlobalJournalofHealthScience,vol. 7,no. 4,pp. 96-109, 2015.
6. "Summary of recommendation statements," Kidney International Supplements,vol. 3,no. 1,pp. 5-14,2013
7. J. C. Longenecker, J. Coresh, M. J. Klag et al. , "Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD," JournaloftheAmericanSocietyof Nephrology, vol. 11, no. 3, pp. 520-529, 2000.
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, "KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease," Kidney International,vol. 3,supplement3,pp. 1-150,2012.
9. A. M. Cueto-Manzano,L. Cortes-Sanabria,H. R. Martinez-Ramirez et al. , "Detection of early nephropathy in Mexican patients with type 2 diabetes mellitus," KidneyInternational,vol. 68, no. 97, pp. S40-S45, 2005.
10. National Kidney Foundation, "KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update," American Journal of Kidney Diseases, vol. 60, no. 5, pp. 850-886, 2012.
11. R. Friedman and J. L. Gross, "Evolution of glomerular filtration rate in proteinuric NIDDM patients," Diabetes Care,vol. 14,no. 5, pp. 355-359, 1991.
12. G. T. Obrador, G. Garcia-Garcia, A. R. Viilaet al. , "Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) Mexico and comparison with KEEP US," KidneyInternational. Supplement, no. 116, pp. S2-S8, 2010.
13. R. Alcazar-Arroyo, L. Orte-Martinez, and A. Otero-Gonzalez, "Estudio de estres oxidativo en Enfermedad Renal Cronica Avanzada," Nefrologia, supplement 3, pp. 3-6, 2008.
14. M. J. Puchades Montesa, M. A. Gonzalez Rico, M. A. Solis Salguero et al. , "Estudio del estrees oxidativo en enfermedad renal croenica avanzada," Nefrologia,vol. 29,no. 5,pp. 464-473, 2009.
15. M. E. Molitch, R. A. DeFronzo, M. J. Franzet al. , "Nephropathy in diabetes," Diabetes Care, vol. 27, no. 1, pp. S79-S83, 2004.
16. P. E. Stevens and A. Levin, "Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline," Annals of Internal Medicine,vol. 158,no. 11,pp. 825-830,2013.
17. B. Radbill, B. Murphy, andD. LeRoith,"Rationaleand strategies for early detection and management of diabetic kidney disease," Mayo Clinic Proceedings,vol. 83,no. 12,pp. 1373-1381,2008.
18. P. N. Van Buren and R. Toto, "Current update in the management of diabetic nephropathy," Current Diabetes Reviews,vol. 9, no. 1, pp. 62-77, 2013.
19. C. Gonzalez Villalpando, M. P. Stern, B. Arredondo Perez et al. , "Nephropathy in low income diabetics: the Mexico City Diabetes Study," Archives ofMedical Research,vol. 27,no. 3,pp. 367-372, 1996.
20. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, and R. R. Holman, "Development and progression of nephro-pathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)," Kidney International,vol. 63, no. 1, pp. 225-232, 2003.
21. J. L. Gross, M. J. De Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz, "Diabetic nephropathy: diagnosis, prevention, and treatment," Diabetes Care,vol. 28,no. 1, pp. 164-176, 2005.
22. R. Montanes Bermudez, S. Gracia Garcia, D. Perez Surribas, A. Marteinez Castelao, and J. Bover Sanjuaen, "Documento de Con-senso. Recomendaciones sobre la valoracioen de la proteinuria en el diagnostico y seguimiento de la enfermedad renal cronica," Nefrologia,vol. 31,no. 3,pp. 331-345,2011.
23. N. Montero, M. J. Soler, M. J. Pascual et al. , "Correlacion entre el cociente proteina/creatinina en orina esporadica y las proteinas en orina de 24 horas," Nefrologia,vol. 32,no. 4,pp. 494-501, 2012.
24. E. Ritz, "Diabetic nephropathy," Saudi Journal ofKidney Diseases and Transplantation,vol. 17,no. 4,pp. 481-490,2006.
25. S. Dronavalli,I. Duka, andG. L. Bakris, "Thepathogenesisof diabetic nephropathy," Nature Clinical Practice Endocrinology and Metabolism,vol. 4,no. 8,pp. 444-452,2008
26. C. K. Kramer, C. B. Leitao, L. C. Pinto, S. P. Siiveiro, J. L. Gross, and L. H. Canani, "Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and nor-moalbuminuria," Diabetes Care, vol. 30, no. 8, pp. 1998-2000, 2007.
27. P. Balakumar, M. K. Arora, J. Reddy, and M. B. Anand-Srivastava, "Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism," Journal ofCardio-vascular Pharmacology, vol. 54, no. 2, pp. 129-138, 2009
28. M. L. Caramori, P. Fioretto, and M. Mauer, "Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions," Diabetes,vol. 52,no. 4,pp. 1036-1040,2003.
29. I. H. De Boer, T. C. Rue, Y. N. Hall, P. J. Heagerty, N. S. Weiss, and J. Himmelfarb, "Temporal trends in the prevalence of diabetic kidney disease in the United States," Journal ofthe American Medical Association,vol. 305,no. 24,pp. 2532-2539,2011
30. Y.-M. Sun, Y. Su, J. Li, and L.-F. Wang, "Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy," Biochemical and Biophysical Research Communications,vol. 433,no. 4,pp. 359-361,2013
31. T. J. Lyons and A. Basu, "Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers," Translational Research,vol. 159, no. 4, pp. 303-312, 2012.
32. W. C. Cushman, G. W. Evans, R. P. Byington et al. , "Effects of intensive blood-pressure control in type 2 diabetes mellitus," The New England Journal of Medicine,vol. 362, no. 17, pp. 15751585, 2010.
33. K. Sharma, N. Gillum, J. L. Boyd, and A. Schmid, "The RosR transcription factor is required for gene expression dynamics in response to extreme oxidative stress in a hypersaline-adapted archaeon," BMC Genomics,vol. 13,no. 1,article351,2012
34. Y. B. Tripathi and D. Yadav, "Diabetic nephropathy: causes and managements," Recent Patents on Endocrine, Metabolic and Immune DrugDiscovery,vol. 7,no. 1,pp. 57-64,2013
35. E. J. Lewis, L. G. Hunsicker, R. P. Bain, and R. D. Rohde, "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy," The New England Journal of Medicine,vol. 329, no. 20, pp. 1456-1462, 1993.
36. B. M. Brenner, M. E. Cooper, D. De Zeeuw et al. , "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy," The New England Journal of Medicine,vol. 345,no. 12,pp. 861-869,2001.
37. A. H. Barnett, S. C. Bain, P. Bouter et al. , "Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy," The New England Journal of Medicine,vol. 351,no. 19,pp. 1952-1961,2004
38. G. Manda, A.-I. Checherita, M. V. Comanescu, and M. E. Hinescu, "Redox signaling in diabetic nephropathy: hypertrophy versus death choices in mesangial cells and podocytes," Mediators of Inflammation,vol. 2015, ArticleID 604208, 13 pages, 2015.
39. B. K. Tiwari,K. B. Pandey,A. B. Abidi,andS. I. Rizvi,"Mark-ers of oxidative stress during diabetes mellitus," Journal ofBio-markers,vol. 2013,ArticleID378790,8pages,2013.
40. M. Kalousova, J. Skrha, and T. Zima, "Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus," Physiological Research,vol. 51,no. 6,pp. 597-604, 2002.
41. N. C. Chilelli, S. Burlina, and A. Lapolla, "AGEs, rather than hyperglycemia, are responsible formicrovascular complications in diabetes: a 'glycoxidation-centric' point of view," Nutrition, Metabolism and Cardiovascular Diseases,vol. 23, no. 10, pp. 913-919, 2013.
42. E. J. Lee and J. H. Park, "Receptor for advanced glycation end-products (RAGE), its ligands, and soluble RAGE: potential biomarkers for diagnosis and therapeutic targets for human renal diseases," Genomics&Informatics,vol. 11, no. 4, pp. 224-229, 2013.
43. J. M. Bohlender, S. Franke, G. Stein, and G. Wolf, "Advanced glycation end products and the kidney," American Journal of Physiology-Renal Physiology,vol. 289,no. 4, pp. F645-F659, 2005.
44. T. Matsui, S. Yamagishi, S. Ueda et al. , "Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant pro-tein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-y, activation," Journal of International Medical Re-search,vol. 35, no. 4, pp. 482-489, 2007.
45. M. T. Coughlan,D. R. Thorburn,S. A. Penfold et al. , "Rage-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes," Journal of the American Society of Nephrology,vol. 20,no. 4,pp. 742-752,2009.
46. M. Arici and J. Walls, "End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?" Kidney International,vol. 59, no. 2, pp. 407-414, 2001.
47. L. B. Pupim, J. Himmelfarb, E. McMonagle, Y. Shyr, and T. A. Ikizler, "Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress," Kidney International,vol. 65,no. 6,pp. 2371-2379,2004.
48. G. Zalba, A. ForUmo, and J. Diez, "Oxidative stress and atherosclerosis in early chronic kidney disease," Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2686-2690, 2006.
49. A. A. Rodriguez-Albanes, E. Barranco-Hernandez, C. A. Alonso-Rodriguez, and J. Soto-Matos, "Comportamiento de la peroxidation lipidica en insuficiencia renal cronica," Revista Cubana de Investigaciones Biomedicas,vol. 22, no. 1,pp. 11-15, 2003.
50. A. Fortuno,O. Beloqui,G. San Jose, M. U. Moreno,G. Zalba, and J. Diez, "Increased phagocytic nicotinamide adenine din-ucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease," Kidney international. Supplement, no. 99, pp. S71-S75, 2005.
51. M. I. Yilmaz, M. Saglam, K. Caglar et al. , "The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine," American Journal of Kidney Diseases,vol. 47, no 1, pp 42-50, 2006
52. Q. Lu, Y. Zhai, Q. Cheng et al. , "The Akt-FoxO3a-manganese superoxide dismutase pathway is involved in the regulation of oxidative stress in diabetic nephropathy," Experimental Physiol-ogy,vol. 98,no. 4,pp. 934-945,2013.
53. G. DeMattia,O. Laurenti,C. Bravi,A. Ghiselli,L. Iuliano,and F. Balsano, "Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients," Metabolism, vol. 43, no. 8, pp. 965-968, 1994.
54. E. N. Wardle, "Cellular oxidative processes in relation to renal disease," American Journal ofNephrology,vol. 25,no. 1,pp. 13-22, 2005.
55. J. Galle, "Oxidative stress in chronic renal failure," Nephrology Dialysis Transplantation, vol. 16, no. 11, pp. 2135-2137, 2001.
56. S. P. Bagby, "Diabetic nephropathy and proximal tubule ROS: challenging our glomerulocentricity," Kidney International,vol. 71, no 12, pp 1199-1202, 2007
57. H. Fujita, H. Fujishima, S. Chida et al. , "Reduction of renal superoxide dismutase in progressive diabetic nephropathy," Journal ofthe American Society ofNephrology,vol. 20,no. 6,pp. 1303-1313, 2009.
58. A. M. Samuni, W. DeGraff, M. C. Krishna, and J. B. Mitchell, "Cellular sites of H2O2-induced damage and their protection by nitroxides," Biochimica et Biophysica Acta (BBA)-General Subjects,vol. 1525, no. 1-2, pp. 70-76, 2001.
59. T. Yamaguchi,K. Sano,K. Takakuraetal. ,"Ebseleninacute ischemic stroke: a placebo-controlled, double-blind clinical trial," Strofce,vol. 29, no. 1, pp. 12-17,1998.
60. S. C. Gupta, S. Patchva, and B. B. Aggarwal, "Therapeutic roles of curcumin: lessons learned from clinical trials," AAPS Journal, vol. 15, no. 1, pp. 195-218, 2013.
61. P. Khajehdehi, M. Pakfetrat, K. Javidnia et al. , "Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-jS and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study," Scandinavian Journal of Urology and Nephrology,vol. 45,no. 5,pp. 365-370,2011.
62. G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, "Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis," The Journal of the American Medical Association,vol. 297,no. 8,pp. 842-857,2007.
63. H. K. Biesalski, T. Grune, J. Tinz, I. Zollner, and J. B. Blumberg, "Reexamination of a meta-analysis of the effect of antioxidant supplementation on mortality and health in randomized trials," Nutrients,vol. 2,no. 9,pp. 929-949,2010.
64. H. Brien, H. Garcia, G. Garcia et al. , "Epidemiologia de la insuficiencia renal cronica en Jalisco," Boletin Colegio Jalisciense de Nefrologia,vol. 5,pp. 6-8,2001.